These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2189148)

  • 21. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent research advances in Parkinson's disease: Part I.
    Friedman J
    R I Med J (1976); 1986 Jul; 69(7):319-22. PubMed ID: 3489271
    [No Abstract]   [Full Text] [Related]  

  • 23. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
    Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
    Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease: disagreements.
    Schulzer M
    Ann Neurol; 1997 Jun; 41(6):833-4. PubMed ID: 9189047
    [No Abstract]   [Full Text] [Related]  

  • 25. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 27. On/off syndrome in Parkinson's disease and intravenous levodopa.
    Clough CG
    Lancet; 1982 Oct; 2(8301):765. PubMed ID: 6125830
    [No Abstract]   [Full Text] [Related]  

  • 28. Progress in Parkinson's disease.
    Calne DB
    N Engl J Med; 1984 Feb; 310(8):523-4. PubMed ID: 6694696
    [No Abstract]   [Full Text] [Related]  

  • 29. Estrogens and the pathophysiology of Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Mar; 45(1-2):119-22. PubMed ID: 2714937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Wearing-off" and beta 2-adrenoceptor agonist in Parkinson's disease.
    Hishida R; Kurahashi K; Narita S; Baba T; Matsunaga M
    Lancet; 1992 Apr; 339(8797):870. PubMed ID: 1347877
    [No Abstract]   [Full Text] [Related]  

  • 31. Electroconvulsive therapy in Parkinson's syndrome with "on-off" phenomenon.
    Balldin J; Edén S; Granérus AK; Modigh K; Svanborg A; Wålinder J; Wallin L
    J Neural Transm; 1980; 47(1):11-21. PubMed ID: 7359119
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease.
    Rico H; Vazquez A; Cabranes JA; Cantizano L; Hernandez ER; Krisnik I; Varela de Seijas E
    Clin Neuropharmacol; 1987; 10(1):87-91. PubMed ID: 3815389
    [No Abstract]   [Full Text] [Related]  

  • 33. Brain monoamines and Parkinsonism.
    Hornykiewicz O
    Psychopharmacol Bull; 1975 Jul; 11(3):34-5. PubMed ID: 1153656
    [No Abstract]   [Full Text] [Related]  

  • 34. Parkinson's disease.
    Marsden CD
    Postgrad Med J; 1992 Jul; 68(801):538-43. PubMed ID: 1437950
    [No Abstract]   [Full Text] [Related]  

  • 35. Hormones and Parkinson's disease.
    Giladi N; Honigman S
    Neurology; 1995 May; 45(5):1028-9. PubMed ID: 7746387
    [No Abstract]   [Full Text] [Related]  

  • 36. Rationale for early use of levodopa in parkinsonism.
    Pincus JH
    Lancet; 1986 Mar; 1(8481):612-3. PubMed ID: 2869319
    [No Abstract]   [Full Text] [Related]  

  • 37. The "on-off" syndrome presenting as a conversion disorder.
    Ross DR; Coffey CE; Walker JI
    Psychosomatics; 1981 Sep; 22(9):812, 817, 821. PubMed ID: 7313061
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of Parkinson's disease.
    Gibberd FB
    Br Med J (Clin Res Ed); 1987 May; 294(6584):1393-6. PubMed ID: 3109671
    [No Abstract]   [Full Text] [Related]  

  • 39. [Parkinson's syndrome. Etiopathogenesis and possibilities of treatment].
    Jovicić A
    Vojnosanit Pregl; 1985; 42(3):206-10. PubMed ID: 3895730
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rational basis for development of a treatment program for Parkinson's disease].
    Jovicić A; Dordević D; Raicević R; Marić D; Jovanović M
    Vojnosanit Pregl; 1995; 52(3):253-60. PubMed ID: 7571543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.